Can a cancer drug treat a rare cardiac disease?
A study by a Yale scientis suggests that dasatinib and similar drugs at low doses could be effective treatment for cardiovascular defects related to Noonan syndrome (NS), a genetic disorder that results in severe heart defects, and should be considered for clinical trials.
Eleven young investigators receive grants to pursue brain and behavior research
Eleven Yale investigators have received Young Investigator Grants from the Brain & Behavior Research Foundation (formerly NARSAD). The grants are among $12 million in new funding intended to lead to breakthroughs in understanding and treating mental illness.
A World Without Cervical Cancer: Preventive Medicine publishes special issue to further global efforts to eliminate deadly disease
Recognizing the urgent public health issue concerning Cervical Cancer, the editorial team of Preventive Medicine is publishing a special issue titled “From Science to Action to Impact: Eliminating Cervical Cancer,” which outlines the required courses of action to eliminate cervical cancer featuring Yale's Dr. Linda Niccolai.
A closer look at the impact of COVID-19 on cardio-oncology
In response to the COVID-19 pandemic, Lauren Baldassarre, MD, and members of the Cardio-Oncology and Imaging Councils of the American College of Cardiology shared recommendations regarding the cardiovascular care of COVID-19-positive patients.
Jawless Lamprey Takes a Bite out of Oncogene Evolution
By carefully tracing the evolution of a select number of cancer-causing genes in a variety of species, the researchers evaluated which animals are — and are not — effective in gauging how an analogue of those genes in humans can lead to cancer. What they found is surprising: jawless fish such as lampreys share significant similarities in these certain genes compared to humans, while fruit flies do not.
New Immunotherapy Treatment for Lung Cancer
More than 200,000 people a year in the United States are diagnosed with non-small cell lung cancers, which make up about 80 percent of all lung cancers. Now, the results of a phase three clinical trial show the immunotherapy drug atezolizumab, also known as Tecentriq, improves survival.Source: ABC News 12
Breast Cancer: Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies
In HER2-positive early stage (stage I-II) breast cancer, several different preoperative (also called neoadjuvant) chemotherapy options exist, each of these is associated with a different rate of complete eradication of cancer from the breast and lymph nodes (called pathologic complete response or pCR). Patients who experience pCR have excellent long term survival.Source: MedicalResearch.com
Treatment with Genetically Altered Viruses Targets and Destroys Ovarian Cancer in Mice
Researchers have successfully eliminated chemotherapy-resistant ovarian cancer cells in mice using a single injection of two viruses genetically combined and altered to be safe, leading to long-term survival and demonstrating a potential breakthrough treatment for women.
Yale Doc Says Lowering Recommended Age For Colon Screening is Critical Following Rise in Colorectal Cancer in Younger Patients
The United States Preventative Services taskforce has released a recommendation that colon cancer screenings start at age 45 instead of 50. It’s because more young people are being diagnosed with colon cancer. Dr. Pamela Kunz says the new recommendation is due to the staggering hike in younger cases of colon cancer.Source: WTNH News 8
The Yale Larynx Lab chosen as cover of Oncotarget, Vol 11, Issue 35
The cover for issue 35 of Oncotarget features Figure 4, "The in vivo pre- or post- topical application of BAY 11-7082 prevents the acidic bile-induced deregulation of cancer-related miRNA markers in 10-day exposed murine HM," by Vageli, et. al.
WHRY Funds Studies on Stroke, Endometrial Cancer, and Addiction to Opioids
Women’s Health Research at Yale today announced funding for three studies investigating sex differences in stroke, endometrial cancer, and alternate pain relief for women recovering from past opioid use who are giving birth via cesarean section.